Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks
Raya Ortega L, Marquez Calderon S, Navarro Caballero J A, Villegas Portero R
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Raya Ortega L, Marquez Calderon S, Navarro Caballero J A, Villegas Portero R. Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks. Seville: Andalusian Agency for Health Technology Assessment (AETSA). Report 5/2006. 2006
Authors' objectives
The aim of this report is to determine whether the use of palivizumab is cost-effective in preventing hospitalisation and morbi-mortality due to syncytial respiratory virus (SRV) infection in premature infants born at 32 to 35 weeks gestational age.
Authors' conclusions
In the population of 32- to 35-week gestational age infants, palivizumab is effective as prophylaxis for SRV infection, but it is not cost-effective.